Clinical trials / NCT04746911
NCT04746911Phase 2Completed

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2022-05-11Actual
Enrollment · participants10Actual
Source updated2026-08-07Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Plasma pharmacokinetic (PK) profile of ARQ-151 cream 0.3% and its major N-oxide metabolite Measure: Incidence of adverse events Measure: Incidence of application site reactions

+ After

Measure: Plasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3% Measure: Plasma Concentration of Major N-oxide Metabolite Following Daily Application of Roflumilast Cream 0.3% Measure: Number of Participants With an Adverse Event (AE) Measure: Number of Participants With Application Site Reactions

Check registry source